You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Generation of Human Hepatocytes

    SBC: IN VIVO TECHNOLOGIES            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this project is to produce "humanized" livers in large animal models such as sheep and pigs that can serve as a reliable source of significant numbers of functional human hepatocytes. The isolated human hepatocytes and/or "humanized" livers can be used for drug toxicity studies as well as for possible clinical use in patients with liver failure. Tra ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  2. A Peptide-Based Vaccine to Nicotine

    SBC: Prommune, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The primary objective of this Phase I STTR project is to develop an effective, peptide-based nicotine vaccine for use in humans capable of inducing a robust, nicotine-specific antibody (Ab) response with little or no inflammatory side effects. This will be accomplished by a vaccine design in which a conformationally biased, response-selective agonist Of C5a ( ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  3. Plasma Diagnostic for Alzheimer's Disease Pathology

    SBC: SAMARITAN PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Presently, there exists no simple minimally invasive test, such as a blood test, that can differentiate patients affected by Alzheimer's disease (AD) from healthy individuals. Our long-term goal is to develop new strategies for determining prognosis or predicting response to therapy. This will provide tools to improve clinical decision-making in the care of AD ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  4. SP004, a sigma-1 ligand with AchE inhibition properties

    SBC: SAMARITAN PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The acetylcholinesterase inhibitors (AchEI) are currently the most broadly used drugs to treat AIzheirmer's disease (AD). Unfortunately none of the beneficial effect lasts for more than a short two years time period, probably due to the progressive degeneration of the cholinergic neurons. This indicates that aiming at the same time at another target distinct to ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  5. A Dual Molecular/Tumor Targeting Therapy for PanCa

    SBC: SYNERGENE THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Approximately 30,000 people in the United States are diagnosed each year with pancreatic cancer (PanCa). Over 90% of these will die of the disease making PanCa one of the most devastating human malignancies. The current 5-year survival rate of less than 4% has changed little in the last 20 years despite improvements in therapy including the introduction of ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  6. Enhancement of Tumor-Targeted Transgene Expression

    SBC: SYNERGENE THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): In this application, the long-term goal is the development of an effective tumor-targeting lipoplex for systemic treatment of pancreatic cancer (PanCa), which has one of the worst prognosis of all human malignancies. Our previous studies indicate that cancer cells can be sensitized to radiation/chemotherapy via p53 restoration ,using a tumor-targeting liposomal ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  7. The Molecular Culture

    SBC: TRANSGENOMIC, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): In the clinical setting, molecular microbiologic detection methods have classically focused on a single microorganism or a small group of microorganisms. Broad range molecular detection of bacteria in clinical specimens is an approach that parallels a conventional culture-based approach, may be more rapid, and offers the possibility of identifying so-called "n ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  8. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: 103

    ABSTRACT Pancreatic cancer PC is an extremely aggressive malignancy with one of the worst prognoses of all cancers with a median survival of less than one year and an overall year survival of andlt With marked resistance to chemo and radiotherapies surgery is the only curative option In patients with localized disease and no lymph node or extra pancreatic metastases complete surgical ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government